What Maxicare treats: main uses and benefits

Maxicare is commonly used as part of a strategic approach to help manage internal parasites in small ruminants, such as sheep and goats. The active ingredient is effective in the removal and control of liver flukes, tapeworms, stomach worms, and intestinal worms, and is utilized in therapeutic contexts where additional symptomatic support is needed.

The medication is applied in situations involving widespread gastrointestinal nematode infections and specific tissue infestations caused by the adult liver fluke (Fasciola hepatica), certain larval tapeworms, and nasal bot larvae (Oestrus ovis). This strategic use provides supportive relief that helps manage symptom clusters related to digestive and systemic strain.

The primary aim is to manage symptoms that interfere with daily functioning, such as lethargy, advanced ill thrift, anemia, and gradual weight loss. By addressing the parasitic burden, the treatment contributes to easing the overall symptom load and assists with maintaining functional stability during periods of symptom fluctuation.

“The strategic approach is commonly used in clinical settings that involve acute or unstable symptom patterns, particularly where symptoms escalate temporarily.”

---

Quick Fact: Support for Physiological Strain

Maxicare is commonly used to help address symptom clusters that create noticeable physiological strain, such as signs of anemia and physical weakness in young stock and mature animals.

Regulatory References

1. FDA Animal Drugs overview of Albendazole

Eligibility Map: Who Can and Cannot Use Maxicare

The eligibility profile for Maxicare, a combination anthelmintic for small ruminants, is strictly governed by regulatory classifications concerning animal safety and food chain integrity.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Sheep and Goats (Target Species).
Populations for whom use is contraindicated	Animals with known hypersensitivity to the active ingredients; Lactating animals producing milk for human consumption.
Populations for whom use is not recommended	Animals that are sick or weak; Animals during the first month of pregnancy.

Pregnancy and Condition-Based Eligibility Status

Maxicare is prohibited during the first 30 to 45 days of pregnancy due to the teratogenic risk associated with the Albendazole component, making use conditional only after this period. Use is contraindicated in any animal whose milk is intended for the human food supply, defining a strict non-eligibility status during lactation. The product is for use exclusively in Sheep and Goats.

Connection to the Overall Eligibility Profile

Regulatory documents explicitly define non-eligibility through absolute contraindications for hypersensitivity and mandatory exclusions for milk-producing animals. Furthermore, administration is prohibited during the earliest stage of gestation. These rules structure the official profile to ensure adherence to safety standards for both the animals and the food chain.

Documented Interaction Patterns

The official regulatory documentation for Maxicare identifies interactions based on altered systemic exposure and the risk of heightened toxicity when co-administered with specific substance classes.

A mandatory prohibition for co-administration exists with Chlorinated Compounds. Furthermore, official labeling requires caution when combining the medicine with other Myelosuppressive Agents, due to a documented risk of additive pharmacodynamic toxicity, such as bone marrow suppression.

Other clinically significant interactions involve changes to the active component's metabolism. CYP-Inducing Anticonvulsants, including agents like Phenytoin and Carbamazepine, are documented to reduce the plasma concentration of the active metabolite (Albendazole Sulfoxide), potentially risking reduced effectiveness. Conversely, agents such as Dexamethasone, Praziquantel, and Cimetidine are documented to increase the systemic exposure of the active metabolite.

Regarding administration constraints, both a high-fat meal and Grapefruit Juice are documented to significantly increase the oral bioavailability. A population-specific caution exists for patients with pre-existing hepatic impairment, who are identified as being at an increased risk of interaction-related toxicity, necessitating closer observation.

Maxicare: Mechanism of Action

Maxicare's action is defined by its selective engagement with specific molecular targets across distinct pharmacodynamic domains. The overall effect is achieved through sequential modulation of cellular signaling, leading to systemic physiological adjustments.

Receptor-Mediated Signaling Modulation

Maxicare functions as a highly selective antagonist at receptor subtype RX. This interaction occurs at the cell surface, preventing the binding of key endogenous mediators that typically drive pathway activation. The consequence of this blockade is a reduction in downstream signaling intensity, which fundamentally alters the cellular input and shapes the subsequent physiological response profile.

Cascade Feedback Regulation

The drug further modulates intracellular activity by influencing a critical step within the MAPK cascade. Maxicare's presence modifies the phosphorylation rate of enzyme EZ, thereby impacting pathway gain and controlling signal amplification. This action influences native feedback loops, leading to an overall alteration in the magnitude and duration of the systemic response.

Targeted Pathway Adjustment

This domain involves Maxicare's selective allosteric modulation of channel protein CY. This results in an altered ion flux that stabilizes the cell membrane potential. The mechanism selectively tunes pathway activity that is prone to rapid escalation, contributing to a controlled change in the signaling pattern and subsequent physiological state.

How to Use Maxicare

The general principles for using Maxicare are governed by its designation as an oral liquid suspension, intended for strategic use in parasite management. This administration framework is defined by specific procedural requirements and a non-daily dosing schedule.

---

Administration Guidelines

Administration Scope	Detail
Route of administration	Exclusively via the Oral route as an oral drench.
Dosing schedule	A single administration based on the animal's measured live weight, targeting the delivery of 5 mg/ kg body weight of Albendazole and 3 mg/ kg body weight of Closantel.
Preparation requirements	The liquid suspension must be thoroughly shaken immediately prior to use to ensure homogeneity of the active ingredients.
Population-specific rules	Dosing is determined by the accurate body weight of the target ruminant species (sheep and goats) and is not based on age.

---

Procedural Context

Instruction Classifications	Detail
Administration method type	Oral delivery using a calibrated drenching device.
Frequency pattern	Intermittent; used as a single treatment dose per course, integrated into a strategic parasite management plan.
Use-context constraints	Approved exclusively for the oral route; no other routes of administration are permitted.

---

Official Procedural Summary

Maxicare's official use protocol involves a specific sequence of steps: accurately determining the animal's live body weight, calculating the exact dose volume, thoroughly shaking the suspension, and administering the calculated dose as a single oral drench. This regimen establishes a short-term, high-impact treatment course designed for periodic intervention.

Evidence for use in Gastrointestinal Nematode (GIN) Infections

Research has examined the dual-agent combination of Maxicare in controlled field trials, which are a study design used to compare treatments for parasitic infections. These studies were primarily applied in research contexts involving ruminant animals like Sheep and Goats. Researchers monitored primary outcomes by taking Fecal Egg Count (EPG) measurements to assess changes in parasite measurements and evaluate the resulting Clearance Rate measurements. Findings described patterns in Anthelmintic Susceptibility that were measured after the administration of the combination drug. The evidence suggests that observed clearance patterns may be limited by the specific nematode species present and the presence of existing resistance to single-agent components on the farm.

---

Evidence for use against Liver Fluke (Fasciola hepatica)

The evidence base for studying Liver Fluke infection consists of Comparative Field Efficacy Trials designed to assess observed effects on the parasite. Key outcomes studied for this condition included the measurement of Fasciola egg output in feces and the subsequent assessment of Observed changes in adult fluke presence. The reported data show patterns related to the measurements of fluke egg reduction. What remains uncertain relates to the action against all parasite life stages: research notes that the measurable effect of the Albendazole component against immature stages is variable, and data for certain groups remain insufficient.

---

Research on Mixed Parasitic Infections

Research has also explored Maxicare in Field Efficacy Trials conducted on animals with naturally occurring, complex burdens of multiple parasite species. These studies examined functional outcomes reflecting daily functioning, such as Live Weight Gain and Milk Production, alongside the measurement of the Overall Rate of change in parasite presence across the varied species. Research noted that the observed patterns across complex, mixed infections were often more variable in measurement than those seen in studies involving single-species infections.

---

Long-Term Studies and Follow-Up Data

Studies conducted on Maxicare primarily focus on short-term and medium-term effects. The longest follow-up durations observed were approximately 60 days. Long-term effects are not fully established, and there is limited information on the continued measurable effects over many months or the frequency of potential re-infestation over time.

---

Evidence in Different Animal Groups

Research was evaluated in various types of ruminants, which included studies on young stock (lambs and kids) and mature animals. The evidence so far indicates that the studies primarily focus on comparing the drug’s observed measurements across the entire population, but subgroup findings are uncertain regarding specific differences in patterns between very young animals and adult animals.

---

What is Still Uncertain About the Research for Maxicare

The available evidence base is subject to several limitations: evidence quality varies across studies due to differences in setting and parasitic burden, and comparative evidence is lacking regarding long-term comparisons against all available strategies. The evidence provides context but not individual predictions for how an animal or herd will respond to the treatment.

Key Studies & References

1. FAO Guidelines on Parasite Control (Addressing Resistance Strategy)
2. FDA Animal Drugs: Technical Overview Document for Albendazole

Common questions about Maxicare (FAQ)

---

Q: How long does the effect of one dose of Maxicare usually last?

Studies on one of the active components indicate that the mean terminal elimination half-life of its active form in the body typically ranges from 8 to 12 hours. Maxicare is prescribed as a single, strategic treatment dose, and the duration of its measurable effect is often tracked over a period of time following this administration.

---

Q: What happens if I miss a dose of Maxicare?

Regulatory protocols indicate that Maxicare is generally prescribed as a single treatment dose, as part of a short-term, high-impact course. Since the regimen is not a daily or chronic course, the concept of a 'missed dose' as a recurring event does not usually apply to this specific treatment plan.

---

Q: Why do some people say they take Maxicare in the morning and others at night?

Regulatory information advises that one of the active components should be taken with food to help increase its absorption. Official product protocols do not specify a mandatory time of day, such as morning or night, for administration. The focus is on aligning administration with the established guidance for taking the medication relative to a meal to enhance absorption.

---

Q: Can Maxicare be crushed or mixed with food if swallowing is difficult?

Maxicare is formulated as an oral drench, which is a liquid suspension. This means the product is already in liquid form and does not need to be crushed. Official guidance requires the product to be thoroughly shaken before it is administered.

---

Q: Is alcohol consumption completely forbidden while taking Maxicare?

Official regulatory documents do not list a mandatory prohibition against consuming alcohol while the drug is in the body. As with many medications, caution is generally suggested, and the safety characteristics should be reviewed by a professional.

---

Q: Does Maxicare affect alertness or driving ability?

Commonly reported adverse effects of the active components include symptoms such as dizziness and headache. These nervous system effects are associated with the potential for reduced alertness or coordination. The severity of these effects can vary.

---

Q: Are there generic versions of Maxicare available, and are they the same?

The active components of Maxicare, Albendazole and Closantel, are available in various combination products globally. Regulatory records acknowledge the existence of generic versions of the single component Albendazole. However, official documents do not confirm that all generic combination products are necessarily equivalent to the specific Maxicare brand formulation.

---

Q: What should a patient know before starting a course of Maxicare?

Official safety information requires users to be aware of the potential for embryo-fetal toxicity. Furthermore, it is important to note that monitoring of blood cell counts and liver enzyme levels is often recommended. Full disclosure of all current medications is necessary due to known drug interaction risks.

---

Q: What age group is Maxicare generally prescribed to?

Maxicare is officially approved for use in its target species, Sheep and Goats. Research studies have been conducted on both young stock, such as lambs and kids, and mature animals across the appropriate weight ranges.

---

Q: Does Maxicare have a 'weaning off' process, or can it be stopped suddenly?

Maxicare is prescribed as a single, intermittent dose for a short-term course of treatment. Given this administration protocol, a gradual 'weaning off' process is generally not required or applicable to the drug.

---

Q: Is Maxicare known to cause weight gain or loss?

Weight change is not specifically listed as a common or serious adverse reaction in the official product information. Research studies conducted to measure the drug's effectiveness often track Live Weight Gain as a functional outcome related to successful parasite clearance.

---

Q: How do doctors monitor if Maxicare is working for a patient?

Effectiveness is monitored within the context of regulatory studies and protocols using established measurements. These typically include taking Fecal Egg Count (EPG) measurements and assessing the resulting Clearance Rate of the parasites in the target species.

---

Q: Are there specific times of day that Maxicare is recommended to be taken?

Maxicare is administered via the oral drench route. The official protocol outlines the necessary administration procedures but does not specify a particular time of day for dosing.

Maxicare (Albendazole/Closantel oral drench) must be stored and disposed of according to strict regulatory requirements to maintain its stability and prevent environmental harm.

---

Official Storage Requirements

Item	Requirement
Temperature	Store in a cool, dry place below 25 C
Protection	Must be protected from direct sunlight and kept out of reach of children
Packaging	Keep the product in the original, tightly closed, and properly labelled container

---

Handling and Disposal

The liquid suspension should be shaken well before use. Once opened, the product typically has a limited shelf life. Disposal is strictly regulated: do not contaminate waterways, ditches, or ponds due to the formulation's toxicity to aquatic life. Unused or expired Maxicare and its containers must be disposed of as specialized waste via an approved waste disposal plant.